scholarly journals Safeguarding COVID-19 and cancer management: drug design and therapeutic approach

2021 ◽  
Vol 1 ◽  
pp. 77
Author(s):  
Nanasaheb Thorat ◽  
Sabrina Pricl ◽  
Abdul K. Parchur ◽  
Sandeep B. Somvanshi ◽  
Qifei Li ◽  
...  
Keyword(s):  
Health Care ◽  
Cancer Patients ◽  
Infection Risk ◽  
Data Driven ◽  
Clinical Settings ◽  
Treatment Protocols ◽  
Cancer Management ◽  
Clinical Cohort ◽  
Demographic Features ◽  
Overall Mortality

Recent clinical cohort studies have highlighted that there is a three-fold greater SARS-Cov-2 infection risk in cancer patients, and overall mortality in individuals with tumours is increased by 41% with respect to general COVID-19 patients. Thus, access to therapeutics and intensive care is compromised for people with both diseases (comorbidity) and there is risk of delayed access to diagnosis. This comorbidity has resulted in extensive burden on the treatment of patients and health care system across the globe; moreover, mortality of hospitalized patients with comorbidity is reported to be 30% higher than for individuals affected by either disease. In this data-driven review, we aim specifically to address drug discoveries and clinical data of cancer management during the COVID-19 pandemic. The review will extensively address the treatment of COVID-19/cancer comorbidity; treatment protocols and new drug discoveries, including the description of drugs currently available in clinical settings; demographic features; and COVID-19 outcomes in cancer patients worldwide.

scholarly journals Cancer Management Practices during the Novel Coronavirus Disease 2019 (COVID-19) Pandemic

2020 ◽  
pp. 22-28
Author(s):  
Tahseen Alrubai ◽  
Arwa Mohsun Khalil ◽  
Rasha Zaki
Keyword(s):  
Health Care ◽  
Cancer Patients ◽  
Management Practices ◽  
Delivery Of Care ◽  
Cancer Management ◽  
Treatment Services ◽  
Cancer Services ◽  
Potential Risks ◽  
Limited Health ◽  
Novel Coronavirus

The COVID-19 pandemic has significantly impacted the management, treatment, and delivery of care to cancer patients. This impact has extended beyond patient care to include logistics, administration, and distribution of increasingly limited health care resources in cancer management healthcare institutions. Based on the collaborative experience of the management, administration, and medical staff at AL-Amal National Hospital (a tertiary health care institution delivering cancer management and treatment services in Baghdad, Iraq), measures were taken and recommendations were carefully formulated to safely proceed with therapy for cancer patients amid the current COVID-19 Pandemic. We hereby review and present AL-Amal National Hospital’s urgent plan to ensure that vital cancer services can still be delivered safely taking into consideration all the potential risks and benefits during this pandemic. Keywords: COVID-19; Coronavirus; SARS-CoV-2; Cancer

IMPACT OF COVID-19 ON CANCER CARE

2021 ◽  
pp. 239-243
Author(s):  
Harindra Sandhu ◽  
Lokavarapu Manoj Joshua ◽  
Dhivakar S ◽  
Rajkumar Kottayasamy Seenivasagam ◽  
Farhanul Huda ◽  
...  
Keyword(s):  
Health Care ◽  
Cancer Patients ◽  
Cancer Care ◽  
English Language ◽  
Virus Disease ◽  
Care Delivery ◽  
Care Facility ◽  
Treatment Protocols ◽  
Corona Virus ◽  
The Impact

The Corona Virus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) has signicantly changed health care delivery to cancer patients. We have reviewed the available literature on COVID-19 to provide comprehensive information about the impact on the delivery of health care in Cancer Care Facility and adaptations in oncological services. We carried out a literature search in English language using online databases PubMed, Up To Date and Embase with keywords: ‘COVID-19’, ‘coronavirus’ and ‘SARS-CoV-2’, ‘cancer’ from January 2020 to 30th June 2020 focusing on cancer care and different strategies to continue surgical services to cancer patients. Here, we have summarized all currently available information regarding the global impact on the delivery of surgical oncological care and adaptations in Cancer Treatment Protocols due to COVID-19 disease.

Clinical and sociodemographic data of cancer patients seeking out-patient based psycho-oncological psychotherapy.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e19610-e19610
Author(s):  
Jens Peter Panse ◽  
Evangelia Athanatou ◽  
Clarissa Kayser ◽  
Marike Anna Simon ◽  
Susanne Singer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Health Care ◽  
Cancer Patients ◽  
Health Care Services ◽  
Private Insurance ◽  
Psychosocial Care ◽  
Median Number ◽  
Treatment Protocols ◽  
Cancer Subtypes ◽  
Care Services

e19610 Background: Although there is a defined need for out-patient psychosocial care for cancer patients, data about out-patient psycho-oncological health care services and patients’ usage of ambulatory infrastructure outside certified cancer centres are scarce. Methods: We retrospectively analyzed charts and treatment protocols from 1,369 patients treated between 1998 and 2009 in a psycho-oncology (PO) practice retrieving socio-demographic and cancer-specific data plus data regarding PO intervention. Results: Of 1,180 patients analysed so far, 808 were documented cancer patients and 372 were relatives or friends of cancer patients. Median age of cancer patients was 50 (range 21-81) years, the majority being female (91%). Although PO interventions are not generally covered by most health care insurances in Germany, 87.7% of patients had public health insurance and only 12.7% had private insurance. 62,5% of patients (n=505) were diagnosed with breast cancer, followed by colorectal cancer (n=46), ovarian cancer (n=42), leukemia/lymphoma (n=38) and lung cancer (n=34), although all types of malignancies were represented. 60.1% received curative and 20.3% palliative treatment, while 19.6% could not specify their treatment intention. 503/663 (n=186 not specified) patients had at least one child with 39.5% being less than 18 years of age. 75.9% (176/232) had received high school education, and 37.1% (151/407) were actively working, while 40.3% (164/407) were incapable of work or on retirement pay (22.6%, 92/407). Half of the patients (50.2%) were Aachen residents, while the other half resided within a 50 km radius. Median number of therapy sessions was 12 (range 1-97). Other treatment specific aspects are still being analysed and will be presented at the meeting. Conclusions: Despite the clear demand for all cancer patients, the majority of cancer patients actively seeking out-patient psycho-oncological support are women with breast cancer, while men and other cancer subtypes are clearly underrepresented. Better information, optimized resources, allocation strategies and comprehensive coverage of PO services are needed in order to address more cancer patients with psycho-social distress.

Standardization and Personalized Medicine Using Quantitative EEG in Clinical Settings

2019 ◽  
pp. 155005941987494
Author(s):  
André W. Keizer
Keyword(s):  
Health Care ◽  
Clinical Practice ◽  
Personalized Medicine ◽  
Treatment Effectiveness ◽  
Diagnostic Procedures ◽  
Quantitative Eeg ◽  
Clinical Settings ◽  
Validity And Reliability ◽  
Treatment Protocols ◽  
Normative Database

Two major trends have been dominant in health care in recent years. First, there is a growing consensus that standardization of health care procedures and methods can result in improved effectiveness and safety of treatments. Second, there is increased interest in “personalized medicine,” which refers to the tailoring of treatments to individual patients. Here I discuss how these trends apply to the field of quantitative EEG (qEEG), where de-artifacted resting state EEGs of individuals are compared with a normative database in order to assess clinically meaningful deviations, which can be used for diagnostic procedures, to guide personalized treatment protocols, and to assess treatment effectiveness. Standardized and automated de-artifacting procedures are increasingly being used in scientific research and in clinical practice. The advantages of these procedures over manual de-artifacting will be discussed. The results of a systematic comparison between 2 commonly used qEEG databases show that these databases produce very comparable results, illustrating not only the validity and reliability of both databases but also the opportunity to move forward to a standardized use of qEEG in clinical practice. Finally, the standardization of qEEG interpretation as both a diagnostic and treatment selection tool provides an example of how qEEG can merge both personalized medicine and standardization in the treatment of psychological disorders.

Cancer Patients' and Health Care Providers' Perspectives on Smoking Relapse

2008 ◽  
Author(s):  
Vani N. Simmons ◽  
Erika B. Litvin ◽  
Riddhi Patel ◽  
Paul B. Jacobsen ◽  
Judith McCaffrey ◽  
...  
Keyword(s):  
Health Care ◽  
Cancer Patients ◽  
Health Care Providers ◽  
Care Providers ◽  
Smoking Relapse

Cancer Biomarker Discovery for Precision Medicine: New Progress

2020 ◽  
Vol 26 (42) ◽  
pp. 7655-7671 ◽  
Author(s):  
Jinfeng Zou ◽  
Edwin Wang
Keyword(s):  
Precision Medicine ◽  
Cancer Patients ◽  
Clinical Application ◽  
Liquid Biopsy ◽  
Biomarker Discovery ◽  
Deep Understanding ◽  
Genetic Mutation ◽  
Data Driven ◽  
Novel Approaches ◽  
Functional Biomarkers

Background: Precision medicine puts forward customized healthcare for cancer patients. An important way to accomplish this task is to stratify patients into those who may respond to a treatment and those who may not. For this purpose, diagnostic and prognostic biomarkers have been pursued. Objective: This review focuses on novel approaches and concepts of exploring biomarker discovery under the circumstances that technologies are developed, and data are accumulated for precision medicine. Results: The traditional mechanism-driven functional biomarkers have the advantage of actionable insights, while data-driven computational biomarkers can fulfill more needs, especially with tremendous data on the molecules of different layers (e.g. genetic mutation, mRNA, protein etc.) which are accumulated based on a plenty of technologies. Besides, the technology-driven liquid biopsy biomarker is very promising to improve patients’ survival. The developments of biomarker discovery on these aspects are promoting the understanding of cancer, helping the stratification of patients and improving patients’ survival. Conclusion: Current developments on mechanisms-, data- and technology-driven biomarker discovery are achieving the aim of precision medicine and promoting the clinical application of biomarkers. Meanwhile, the complexity of cancer requires more effective biomarkers, which could be accomplished by a comprehensive integration of multiple types of biomarkers together with a deep understanding of cancer.

Telemedicine in Cancer Care

2018 ◽  
pp. 540-545 ◽  
Author(s):  
S. Joseph Sirintrapun ◽  
Ana Maria Lopez
Keyword(s):  
Health Care ◽  
Access To Care ◽  
Cancer Care ◽  
Symptom Management ◽  
Lifestyle Modification ◽  
Clinical Settings ◽  
Home Based ◽  
Home Based Care ◽  
Care Costs ◽  
Improve Access

Telemedicine uses telecommunications technology as a tool to deliver health care to populations with limited access to care. Telemedicine has been tested in multiple clinical settings, demonstrating at least equivalency to in-person care and high levels of patient and health professional satisfaction. Teleoncology has been demonstrated to improve access to care and decrease health care costs. Teleconsultations may take place in a synchronous, asynchronous, or blended format. Examples of successful teleoncology applications include cancer telegenetics, bundling of cancer-related teleapplications, remote chemotherapy supervision, symptom management, survivorship care, palliative care, and approaches to increase access to cancer clinical trials. Telepathology is critical to cancer care and may be accomplished synchronously and asynchronously for both cytology and tissue diagnoses. Mobile applications support symptom management, lifestyle modification, and medication adherence as a tool for home-based care. Telemedicine can support the oncologist with access to interactive tele-education. Teleoncology practice should maintain in-person professional standards, including documentation integrated into the patient’s electronic health record. Telemedicine training is essential to facilitate rapport, maximize engagement, and conduct an accurate virtual exam. With the appropriate attachments, the only limitation to the virtual exam is palpation. The national telehealth resource centers can provide interested clinicians with the latest information on telemedicine reimbursement, parity, and practice. To experience the gains of teleoncology, appropriate training, education, as well as paying close attention to gaps, such as those inherent in the digital divide, are essential.

Sign in / Sign up

Export Citation Format

Share Document